PD-L1 >= 1%
About
Biomarker type: Protein expression
Marker: PD-L1
Unit: Tumor Proportion Score (TPS)
Equality: >=
Value: 0.01
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Atezolizumab | |
| FDA (2) HC (2) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (2) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Ipilimumab, Nivolumab | |
| FDA (2) HC (1) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Pembrolizumab | |
| FDA (2) HC (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Pembrolizumab | |
| HC (2) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| HC (1) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| HC (1) | ER negative, HER2-negative, PD-L1 >= 1%, PR negative | Invasive Breast Carcinoma | Atezolizumab, Nab-paclitaxel | |
| HC (1) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Nivolumab, Oxaliplatin |